Fig. 3: Evaluation of CREB5’s promotion of IL13RA2.

A Bar chart depicts the counts of unique cell surface proteins increased by CREB5 overexpression in MDA-MB-231 and HCC1806 cell lines, as categorized by set ranges of abundance ratios. B Venn diagram compares cell surface proteins with greater than 10- fold changes in MDA-MB-231 and HCC1806 cell lines. The overlapping proteins (n = 3) are detailed in the table beneath. IL13RA2 mRNA expression in C MDA-MB-231 and D HCC1806 cell lines with CREB5 or luciferase overexpressed in 2D and 3D cultures. Box plots display median expression levels with whiskers extending to minimum and maximum values. p ** < 0.01, **** < 0.0001. E Log2 fold changes in IL13RA2 expression with respect to primary BC biopsies from patients with BCBMs, as organized by BC subtypes from Cosgrove et al.¹². Each circle represents the change in expression of a paired sample (n = 44). The dotted line at 0 indicates no change in expression. F Percentage of BCBM samples with IL13RA2 expression increased from the primary BC sample by 0–100%, ≥100%, or ≤0%. Change in IL13RA2 expression is shown across BC subtypes including basal (n = 16), HER2 (n = 9), luminal A (n = 11), and luminal B (n = 8). G Bar graph displays the frequency of IL13RA2 genetic alterations including high mRNA expression, amplification, and homozygous deletions, across multiple cancer types from TCGA.